{
  "docId": "019de077-72f9-7549-be02-1cb8598bb783",
  "docSlug": "e2ad68eb257d4e7a3f142ed0c8be9c7f",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 36,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 24,
  "notes": "The slide presents TEAE (Treatment-emergent adverse events) and SAE (Serious adverse events) data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-72f9-7549-be02-1cb8598bb783/14",
  "deckHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783",
  "deckJsonHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783.json",
  "deckAnchorHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.555,
        "w": 0.333,
        "x": 0.644,
        "y": 0.232
      },
      "kind": "callout",
      "text": "Key insights: Low discontinuations, GI events mild, Hemoglobin effect consistent, No anemia SAEs, No study withdrawal, Safety profile supports development",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7053a74-3fdc-412c-a363-a107805506fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.47,
        "x": 0.229,
        "y": 0.918
      },
      "kind": "disclaimer",
      "text": "TEAE: Treatment-emergent adverse events; SAE: Serious adverse events",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f540df5-d347-48aa-acd9-af50badb5f3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.455,
        "w": 0.592,
        "x": 0.039,
        "y": 0.332
      },
      "kind": "table",
      "text": "TEAEs, EBO+OBR (N=39), Placebo+OBR (N=41), Mild, Moderate, Severe, Life threatening, Death, SAEs, Drug discontinuation due to TEAE",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f36c56d5-3ce4-4b4c-97a9-488293b0205d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.738,
        "x": 0.025,
        "y": 0.045
      },
      "kind": "title",
      "text": "EBO Appears Generally Well Tolerated in Phase 2 Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dddf7f9b-ed2b-4a4d-832d-8a01ebe96e99",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "bdae8f9a-7799-47a4-867b-a75e432e9aad",
      "evidence": "TEAEs, EBO+OBR (N=39), Placebo+OBR (N=41), Mild, Moderate, Severe, Life threatening, Death, SAEs, Drug discontinuation due to TEAE",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "cc73c19c-ae43-4e15-b621-ac27bebabaca",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Phase 2 top-line results and clinical POC",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}